Asparaginase-associated Pancreatitis: a Study on Phenotype and Genotype in the NOPHO ALL2008 Protocol

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2016 Jul 26

PMID 27451978

Citations 27

Authors

B O Wolthers

T L Frandsen

J Abrahamsson

B K Albertsen

L R Helt

M Heyman

O G Jonsson

L T Korgvee

B Lund

R A Raja

K K Rasmussen

M Taskinen

M Tulstrup

G E Vaitkeviciene

R Yadav

R Gupta

K Schmiegelow

Affiliations

Soon will be listed here.

Abstract

Asparaginase (ASP)-associated pancreatitis (AAP) occurs during acute lymphoblastic leukemia treatment. Among 1285 children (1.0-17.9 years) diagnosed during July 2008-December 2014 and treated according to the Nordic/Baltic ALL2008 protocol, 86 (cumulative incidence=6.8%) developed AAP. Seventy-three cases were severe (diagnostic AAP criteria persisting >72 h) and 13 mild. Cases were older than controls (median: 6.5 vs 4.5 years; P=0.001). Pseudocysts developed in 28%. Of the 20 re-exposed to ASP, 9 (45%) developed a second AAP. After a median follow-up of 2.3 years, 8% needed permanent insulin therapy, and 7% had recurrent abdominal pain. Germline DNA on 62 cases and 638 controls was genotyped on Omni2.5exome-8-v1.2 BeadChip arrays. Overall, the ULK2 variant rs281366 showed the strongest association with AAP (P=5.8 × 10; odds ratio (OR)=6.7). Cases with the rs281366 variant were younger (4.3 vs 8 years; P=0.015) and had lower risk of AAP-related complications (15% vs 43%; P=0.13) compared with cases without this variant. Among 45 cases and 517 controls <10 years, the strongest associations with AAP were found for RGS6 variant rs17179470 (P=9.8 × 10; OR=7.3). Rs281366 is located in the ULK2 gene involved in autophagy, and RGS6 regulates G-protein signaling regulating cell dynamics. More than 50% of AAP cases <10 years carried one or both risk alleles.

Citing Articles

Combination of the CRAC Channel Inhibitor CM4620 and Galactose as a Potential Therapy for Acute Pancreatitis.

Lewis S, Evans D, Tsugorka T, Peng S, Stauderman K, Gerasimenko O Function (Oxf). 2024; 5(4).

PMID: 38984998 PMC: 11237893. DOI: 10.1093/function/zqae017.

The role of Ca signalling in the pathology of exocrine pancreas.

Gerasimenko J, Gerasimenko O Cell Calcium. 2023; 112:102740.

PMID: 37058923 PMC: 10840512. DOI: 10.1016/j.ceca.2023.102740.

A systems approach points to a therapeutic role for retinoids in asparaginase-associated pancreatitis.

Tsai C, Saito T, Sarangdhar M, Abu-El-Haija M, Wen L, Lee B Sci Transl Med. 2023; 15(687):eabn2110.

PMID: 36921036 PMC: 10205044. DOI: 10.1126/scitranslmed.abn2110.

Case report: Hyperosmolar hyperglycemic syndrome secondary to PEG-asparaginase-induced hypertriglyceridemia and pancreatitis.

Mudd Jr T, Fox A, Ghaly M, Keruakous A Front Oncol. 2023; 12:1094964.

PMID: 36741726 PMC: 9893891. DOI: 10.3389/fonc.2022.1094964.

The 2022 George E Palade Medal Lecture: Toxic Ca signals in acinar, stellate and endogenous immune cells are important drivers of acute pancreatitis.

Petersen O Pancreatology. 2022; 23(1):1-8.

PMID: 36539315 PMC: 10809214. DOI: 10.1016/j.pan.2022.12.010.

References

Vrooman L, Supko J, Neuberg D, Asselin B, Athale U, Clavell L . Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2009; 54(2):199-205. PMC: 3706086. DOI: 10.1002/pbc.22225. View

Alvarez O, Zimmerman G . Pegaspargase-induced pancreatitis. Med Pediatr Oncol. 2000; 34(3):200-5. DOI: 10.1002/(sici)1096-911x(200003)34:3<200::aid-mpo7>3.0.co;2-t. View

Knoderer H, Robarge J, Flockhart D . Predicting asparaginase-associated pancreatitis. Pediatr Blood Cancer. 2006; 49(5):634-9. DOI: 10.1002/pbc.21037. View

Holmqvist A, Olsen J, Andersen K, de Fine Licht S, Hjorth L, Garwicz S . Adult life after childhood cancer in Scandinavia: diabetes mellitus following treatment for cancer in childhood. Eur J Cancer. 2014; 50(6):1169-75. DOI: 10.1016/j.ejca.2014.01.014. View

Abecasis G, Auton A, Brooks L, DePristo M, Durbin R, Handsaker R . An integrated map of genetic variation from 1,092 human genomes. Nature. 2012; 491(7422):56-65. PMC: 3498066. DOI: 10.1038/nature11632. View

Samarasinghe S, Dhir S, Slack J, Iyer P, Wade R, Clack R . Incidence and outcome of pancreatitis in children and young adults with acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003. Br J Haematol. 2013; 162(5):710-3. DOI: 10.1111/bjh.12407. View

Stewart A, Fisher R . Introduction: G Protein-coupled Receptors and RGS Proteins. Prog Mol Biol Transl Sci. 2015; 133:1-11. DOI: 10.1016/bs.pmbts.2015.03.002. View

Moricke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, Dordelmann M . Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008; 111(9):4477-89. DOI: 10.1182/blood-2007-09-112920. View

Lund B, Asberg A, Heyman M, Kanerva J, Harila-Saari A, Hasle H . Risk factors for treatment related mortality in childhood acute lymphoblastic leukaemia. Pediatr Blood Cancer. 2011; 56(4):551-9. DOI: 10.1002/pbc.22719. View

10.

Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J . STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2014; 43(Database issue):D447-52. PMC: 4383874. DOI: 10.1093/nar/gku1003. View

11.

Hall J, Crawford H . The conspiracy of autophagy, stress and inflammation in acute pancreatitis. Curr Opin Gastroenterol. 2014; 30(5):495-9. PMC: 4290869. DOI: 10.1097/MOG.0000000000000097. View

12.

Stanulla M, Schrappe M . Treatment of childhood acute lymphoblastic leukemia. Semin Hematol. 2008; 46(1):52-63. DOI: 10.1053/j.seminhematol.2008.09.007. View

13.

Zerbino D, Wilder S, Johnson N, Juettemann T, Flicek P . The ensembl regulatory build. Genome Biol. 2015; 16:56. PMC: 4407537. DOI: 10.1186/s13059-015-0621-5. View

14.

Schmiegelow K, Attarbaschi A, Barzilai S, Escherich G, Frandsen T, Halsey C . Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus. Lancet Oncol. 2016; 17(6):e231-e239. DOI: 10.1016/S1470-2045(16)30035-3. View

15.

Schmiegelow K, Forestier E, Hellebostad M, Heyman M, Kristinsson J, Soderhall S . Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia. 2009; 24(2):345-54. DOI: 10.1038/leu.2009.251. View

16.

Bush W, Moore J . Chapter 11: Genome-wide association studies. PLoS Comput Biol. 2013; 8(12):e1002822. PMC: 3531285. DOI: 10.1371/journal.pcbi.1002822. View

17.

Schmiegelow K, Levinsen M, Attarbaschi A, Baruchel A, Devidas M, Escherich G . Second malignant neoplasms after treatment of childhood acute lymphoblastic leukemia. J Clin Oncol. 2013; 31(19):2469-76. PMC: 3807139. DOI: 10.1200/JCO.2012.47.0500. View

18.

Rubnitz J, Lensing S, Zhou Y, Sandlund J, Razzouk B, Ribeiro R . Death during induction therapy and first remission of acute leukemia in childhood: the St. Jude experience. Cancer. 2004; 101(7):1677-84. DOI: 10.1002/cncr.20532. View

19.

Vilmer E, Suciu S, Ferster A, Bertrand Y, Cave H, Thyss A . Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Children Leukemia Cooperative Group. Leukemia. 2001; 14(12):2257-66. DOI: 10.1038/sj.leu.2401960. View

20.

Hargrave D, Hann I, Richards S, Hill F, Lilleyman J, Kinsey S . Progressive reduction in treatment-related deaths in Medical Research Council childhood lymphoblastic leukaemia trials from 1980 to 1997 (UKALL VIII, X and XI). Br J Haematol. 2001; 112(2):293-9. DOI: 10.1046/j.1365-2141.2001.02543.x. View